| Previous Close | N/A |
| Open | N/A |
| Bid | N/A |
| Ask | N/A |
| Strike | N/A |
| Expire Date | N/A |
| Day's Range | N/A - N/A |
| Contract Range | N/A |
| Volume | |
| Open Interest | N/A |
Simply Wall St.Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week
Key Insights Significantly high institutional ownership implies Syros Pharmaceuticals' stock price is sensitive to...
Business WireSyros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
CAMBRIDGE, Mass., June 13, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a webcast event with medical experts to discuss the unmet need in higher-risk myelodysplastic syndrome (HR-MDS) and the opportunity for tamibarotene to transform the care of newly diagnosed patients with RARA gene overexpression. The event will take place on Tuesday
- GuruFocus.com
Syros Pharmaceuticals Inc (SYRS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Explore key updates on clinical trials, financial shifts, and strategic insights from Syros Pharmaceuticals' Q1 2024 earnings call.
© 2024 Yahoo. All rights reserved.